GPATCH2L
geneOn this page
Also known as FLJ20689FLJ10033
Summary
GPATCH2L (G-patch domain containing 2 like, HGNC:20210) is a protein-coding gene on chromosome 14q24.3, encoding G patch domain-containing protein 2-like (Q9NWQ4).
Predicted to be active in nucleus.
Source: NCBI Gene 55668 — RefSeq curated summary.
At a glance
- GWAS associations: 10
- Clinical variants (ClinVar): 45 total
- MANE Select transcript:
NM_017926
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:20210 |
| Approved symbol | GPATCH2L |
| Name | G-patch domain containing 2 like |
| Location | 14q24.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ20689, FLJ10033 |
| Ensembl gene | ENSG00000089916 |
| Ensembl biotype | protein_coding |
| Entrez | 55668 |
Gene structure
Transcript identifiers
Ensembl transcripts: 16 — 11 protein_coding, 2 retained_intron, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined
ENST00000261530, ENST00000312858, ENST00000553588, ENST00000554125, ENST00000554375, ENST00000554799, ENST00000556109, ENST00000556372, ENST00000556663, ENST00000556675, ENST00000557207, ENST00000557263, ENST00000557542, ENST00000621494, ENST00000930299, ENST00000954001
RefSeq mRNA: 9 — MANE Select: NM_017926
NM_001322026, NM_001322027, NM_001322028, NM_001322029, NM_001322030, NM_001322031, NM_001322032, NM_017926, NM_017972
CCDS: CCDS9848, CCDS9849
Canonical transcript exons
ENST00000261530 — 10 exons
| Exon | Start | End |
|---|---|---|
| ENSE00002533901 | 76151922 | 76151991 |
| ENSE00002603976 | 76201691 | 76214343 |
| ENSE00003535064 | 76173546 | 76173625 |
| ENSE00003564900 | 76195878 | 76195972 |
| ENSE00003567699 | 76154354 | 76155025 |
| ENSE00003617322 | 76171843 | 76172019 |
| ENSE00003639267 | 76180764 | 76180849 |
| ENSE00003641979 | 76177988 | 76178042 |
| ENSE00003642677 | 76176623 | 76176690 |
| ENSE00003686420 | 76166663 | 76166727 |
Expression profiles
Bgee: expression breadth ubiquitous, 259 present calls, max score 95.50.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 17.6731 / max 181.5289, expressed in 1803 samples.
FANTOM5 promoters (4 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 140710 | 16.9923 | 1802 |
| 140715 | 0.4765 | 239 |
| 140711 | 0.1975 | 73 |
| 207306 | 0.0068 | 2 |
Top tissues by expression
286 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| buccal mucosa cell | CL:0002336 | 95.50 | gold quality |
| colonic epithelium | UBERON:0000397 | 91.38 | gold quality |
| adrenal tissue | UBERON:0018303 | 90.78 | gold quality |
| monocyte | CL:0000576 | 88.98 | gold quality |
| cauda epididymis | UBERON:0004360 | 88.65 | gold quality |
| mononuclear cell | CL:0000842 | 88.63 | gold quality |
| calcaneal tendon | UBERON:0003701 | 88.49 | gold quality |
| leukocyte | CL:0000738 | 88.05 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 87.33 | gold quality |
| stromal cell of endometrium | CL:0002255 | 87.01 | gold quality |
| cortical plate | UBERON:0005343 | 86.59 | gold quality |
| ganglionic eminence | UBERON:0004023 | 85.89 | gold quality |
| right testis | UBERON:0004534 | 85.87 | gold quality |
| corpus epididymis | UBERON:0004359 | 85.81 | gold quality |
| caput epididymis | UBERON:0004358 | 85.72 | gold quality |
| gall bladder | UBERON:0002110 | 85.66 | gold quality |
| ventricular zone | UBERON:0003053 | 85.63 | gold quality |
| left testis | UBERON:0004533 | 85.39 | gold quality |
| sural nerve | UBERON:0015488 | 84.98 | gold quality |
| corpus callosum | UBERON:0002336 | 84.96 | gold quality |
| islet of Langerhans | UBERON:0000006 | 84.77 | gold quality |
| rectum | UBERON:0001052 | 84.44 | gold quality |
| testis | UBERON:0000473 | 84.43 | gold quality |
| tendon | UBERON:0000043 | 84.22 | gold quality |
| gastrocnemius | UBERON:0001388 | 84.08 | gold quality |
| tonsil | UBERON:0002372 | 83.98 | gold quality |
| muscle of leg | UBERON:0001383 | 83.97 | gold quality |
| right atrium auricular region | UBERON:0006631 | 83.97 | gold quality |
| bone marrow | UBERON:0002371 | 83.63 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 83.53 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 8.16 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
239 targeting GPATCH2L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-6867-5P | 100.00 | 82.21 | 3464 |
| HSA-MIR-4795-3P | 100.00 | 74.62 | 4024 |
| HSA-MIR-6833-3P | 100.00 | 70.63 | 3197 |
| HSA-MIR-4768-5P | 100.00 | 69.49 | 2861 |
| HSA-MIR-3613-3P | 100.00 | 76.36 | 7965 |
| HSA-MIR-6873-3P | 100.00 | 71.42 | 2626 |
| HSA-MIR-429 | 100.00 | 73.44 | 2698 |
| HSA-MIR-200B-3P | 100.00 | 73.31 | 2693 |
| HSA-MIR-200C-3P | 100.00 | 73.35 | 2685 |
| HSA-MIR-188-3P | 100.00 | 68.76 | 1240 |
| HSA-MIR-126-5P | 100.00 | 72.71 | 3180 |
| HSA-MIR-8485 | 100.00 | 77.57 | 4731 |
| HSA-MIR-196A-1-3P | 99.99 | 72.15 | 2772 |
| HSA-MIR-548AW | 99.99 | 72.57 | 3559 |
| HSA-MIR-3662 | 99.99 | 73.82 | 5684 |
| HSA-MIR-4282 | 99.99 | 75.36 | 6408 |
| HSA-MIR-548C-3P | 99.99 | 74.01 | 7587 |
| HSA-MIR-186-5P | 99.99 | 70.83 | 3707 |
| HSA-MIR-33A-5P | 99.99 | 68.62 | 1055 |
| HSA-MIR-33B-5P | 99.99 | 68.58 | 1062 |
| HSA-MIR-548AN | 99.97 | 70.91 | 2817 |
| HSA-MIR-3148 | 99.97 | 75.06 | 6478 |
| HSA-MIR-3065-5P | 99.97 | 71.56 | 3281 |
| HSA-MIR-1250-3P | 99.96 | 70.04 | 4038 |
| HSA-MIR-1468-3P | 99.96 | 72.74 | 3797 |
| HSA-MIR-590-3P | 99.96 | 74.34 | 6478 |
| HSA-MIR-2110 | 99.96 | 66.68 | 1930 |
| HSA-MIR-9718 | 99.94 | 68.91 | 918 |
| HSA-MIR-335-3P | 99.93 | 73.36 | 4958 |
| HSA-MIR-218-5P | 99.93 | 72.22 | 2103 |
Literature-anchored findings (GeneRIF, showing 1)
- N6-methyladenosine hypomethylation of circGPATCH2L regulates DNA damage and apoptosis through TRIM28 in intervertebral disc degeneration. (PMID:37438603)
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Gpatch2l | ENSMUSG00000021254 |
| rattus_norvegicus | Gpatch2l | ENSRNOG00000010227 |
Paralogs (1): GPATCH2 (ENSG00000092978)
Protein
Protein identifiers
G patch domain-containing protein 2-like — Q9NWQ4 (reviewed: Q9NWQ4)
All UniProt accessions (7): Q9NWQ4, G3V290, G3V3M4, G3V4I8, G3V4L1, G3V553, G3V5D0
UniProt curated annotations — full annotation on UniProt →
Isoforms (3)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9NWQ4-3 | 1 | yes |
| Q9NWQ4-1 | 2 | |
| Q9NWQ4-4 | 4 |
RefSeq proteins (9): NP_001308955, NP_001308956, NP_001308957, NP_001308958, NP_001308959, NP_001308960, NP_001308961, NP_060396, NP_060442 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR051189 | Splicing_assoc_domain | Family |
UniProt features (21 total): modified residue 6, compositionally biased region 4, splice variant 3, sequence conflict 3, region of interest 2, chain 1, cross-link 1, sequence variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9NWQ4-F1 | 51.19 | 0.02 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (7): 91, 447, 449, 196, 31, 86, 88
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 228 (showing top):
PEREZ_TP63_TARGETS, TGACCTY_ERR1_Q2, CACCAGC_MIR138, chr14q24, PEREZ_TP53_AND_TP63_TARGETS, CHANDRAN_METASTASIS_UP, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, STAT1_02, SCGGAAGY_ELK1_02, KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP, MORI_PLASMA_CELL_DN, STAT1_03, PURBEY_TARGETS_OF_CTBP1_NOT_SATB1_DN, GHANDHI_DIRECT_IRRADIATION_UP, ODONNELL_METASTASIS_UP
GO Biological Process (0):
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (1): nucleus (GO:0005634)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| binding | 1 |
| intracellular membrane-bounded organelle | 1 |
Protein interactions and networks
STRING
702 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| GPATCH2L | BLTP3B | A0JNW5 | 614 |
| GPATCH2L | ZNF543 | Q08ER8 | 505 |
| GPATCH2L | IFT43 | Q96FT9 | 475 |
| GPATCH2L | PTPRH | Q9HD43 | 458 |
| GPATCH2L | SVOPL | Q8N434 | 447 |
| GPATCH2L | VPS13C | Q709C8 | 373 |
| GPATCH2L | TTLL5 | Q6EMB2 | 371 |
| GPATCH2L | DHRS7B | Q6IAN0 | 371 |
| GPATCH2L | PPP1R3E | Q9H7J1 | 370 |
| GPATCH2L | ZNF135 | P52742 | 351 |
| GPATCH2L | MACO1 | Q8N5G2 | 348 |
| GPATCH2L | RRP15 | Q9Y3B9 | 348 |
| GPATCH2L | DHX15 | O43143 | 345 |
| GPATCH2L | AGTPBP1 | Q9UPW5 | 334 |
| GPATCH2L | SACK1A | Q86UY5 | 330 |
| GPATCH2L | TSEN2 | Q8NCE0 | 330 |
IntAct
81 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| GPATCH2L | ZNF398 | psi-mi:“MI:0915”(physical association) | 0.670 |
| GPATCH2L | ZNF473 | psi-mi:“MI:0915”(physical association) | 0.670 |
| ZNF398 | GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.670 |
| CSNK2B | NMT2 | psi-mi:“MI:0914”(association) | 0.660 |
| CSNK2A2 | PES1 | psi-mi:“MI:0914”(association) | 0.640 |
| MEOX2 | GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.560 |
| GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.560 | |
| GPATCH2L | ZNF263 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB48 | GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.560 |
| KRTAP10-9 | GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.560 |
| DIP2A | GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZNF165 | GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.560 |
| KRT40 | GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.560 |
| GPATCH2L | CEP70 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TRIM41 | GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.560 |
| GPATCH2L | RBPMS | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB8A | GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.560 |
| GPATCH2L | MDFI | psi-mi:“MI:0915”(physical association) | 0.560 |
| KRTAP4-12 | GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.560 |
| GPATCH2L | LZTS2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| PRDM14 | GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZNF408 | GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.560 |
| THAP1 | GPATCH2L | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (101): GPATCH2L (Two-hybrid), GPATCH2L (Two-hybrid), GPATCH2L (Two-hybrid), GPATCH2L (Two-hybrid), GPATCH2L (Two-hybrid), GPATCH2L (Two-hybrid), GPATCH2L (Two-hybrid), GPATCH2L (Two-hybrid), GPATCH2L (Two-hybrid), ZNF398 (Two-hybrid), PRDM14 (Two-hybrid), ZNF408 (Two-hybrid), CCDC33 (Two-hybrid), CEP70 (Two-hybrid), KRTAP4-12 (Two-hybrid)
ESM2 similar proteins: A0A087WXM9, A0A140LI88, A2AKY4, A4D1E1, A4IGL8, E5FYH0, E9Q3S4, F6ULY3, F7DF15, G3S077, G7H7V7, G7NY55, O13859, O35923, O54952, O88491, P38299, P38398, P46013, P48754, P51587, P97929, Q09MP3, Q28DZ0, Q4V7J0, Q56UN5, Q5DTW7, Q5F2C3, Q5VWN6, Q5VYV7, Q6J6I8, Q6J6J0, Q6NS59, Q77PU6, Q7TSY8, Q7Z570, Q864S8, Q86TB3, Q86XD8, Q8N7Z5
Diamond homologs: Q6PE65, Q7TQC7, Q9NW75, Q9NWQ4, A0JMV4, A4IGK4, A5DEF8, A5DSB5, A6ZRL6, A7TQN2, B2GV05, F4JCU0, O15226, P52756, P53866, P70501, P98175, Q1RMU5, Q59UG4, Q6BYP9, Q6C233, Q6CQ59, Q6DDU9, Q6FP19, Q75E62, Q7TN31, Q8BY02, Q8CH09, Q8IX01, Q8N302, Q91YE7, Q99KG3, Q9UTK6
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
45 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 36 |
| Likely benign | 2 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1657 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 14:76166186:A:AG | donor_gain | 1.0000 |
| 14:76166661:A:AG | acceptor_gain | 1.0000 |
| 14:76166661:AGT:A | acceptor_gain | 1.0000 |
| 14:76166662:G:GG | acceptor_gain | 1.0000 |
| 14:76166662:GT:G | acceptor_gain | 1.0000 |
| 14:76166662:GTG:G | acceptor_gain | 1.0000 |
| 14:76166662:GTGAA:G | acceptor_gain | 1.0000 |
| 14:76171840:TAG:T | acceptor_loss | 1.0000 |
| 14:76171841:A:AG | acceptor_gain | 1.0000 |
| 14:76171842:G:GG | acceptor_gain | 1.0000 |
| 14:76171842:G:GT | acceptor_loss | 1.0000 |
| 14:76172017:GAG:G | donor_gain | 1.0000 |
| 14:76172019:GGTG:G | donor_loss | 1.0000 |
| 14:76172020:GT:G | donor_loss | 1.0000 |
| 14:76172021:T:G | donor_loss | 1.0000 |
| 14:76176689:GA:G | donor_gain | 1.0000 |
| 14:76176691:G:GG | donor_gain | 1.0000 |
| 14:76180762:A:AG | acceptor_gain | 1.0000 |
| 14:76180763:G:GG | acceptor_gain | 1.0000 |
| 14:76180763:GTTCA:G | acceptor_gain | 1.0000 |
| 14:76201590:GAT:G | donor_gain | 1.0000 |
| 14:76166186:A:G | donor_gain | 0.9900 |
| 14:76166191:T:G | donor_gain | 0.9900 |
| 14:76166657:TTACA:T | acceptor_loss | 0.9900 |
| 14:76166659:ACAGT:A | acceptor_gain | 0.9900 |
| 14:76166660:C:G | acceptor_gain | 0.9900 |
| 14:76166661:A:AC | acceptor_loss | 0.9900 |
| 14:76166662:GTGA:G | acceptor_gain | 0.9900 |
| 14:76166723:ACAAG:A | donor_loss | 0.9900 |
| 14:76166724:CAAG:C | donor_loss | 0.9900 |
AlphaMissense
3152 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 14:76154374:T:C | L4P | 0.999 |
| 14:76154386:T:C | L8S | 0.999 |
| 14:76154750:G:C | R129S | 0.999 |
| 14:76154750:G:T | R129S | 0.999 |
| 14:76171849:A:T | D245V | 0.999 |
| 14:76171857:A:C | S248R | 0.999 |
| 14:76171859:T:A | S248R | 0.999 |
| 14:76171859:T:G | S248R | 0.999 |
| 14:76171863:T:A | W250R | 0.999 |
| 14:76171863:T:C | W250R | 0.999 |
| 14:76154398:T:C | L12S | 0.998 |
| 14:76154745:C:A | R128S | 0.998 |
| 14:76154749:G:C | R129T | 0.998 |
| 14:76154749:G:T | R129M | 0.998 |
| 14:76154760:A:G | K133E | 0.998 |
| 14:76154762:G:C | K133N | 0.998 |
| 14:76154762:G:T | K133N | 0.998 |
| 14:76166670:A:C | S224R | 0.998 |
| 14:76166672:C:A | S224R | 0.998 |
| 14:76166672:C:G | S224R | 0.998 |
| 14:76166673:A:C | S225R | 0.998 |
| 14:76166675:T:A | S225R | 0.998 |
| 14:76166675:T:G | S225R | 0.998 |
| 14:76171845:G:C | D244H | 0.998 |
| 14:76171846:A:T | D244V | 0.998 |
| 14:76171848:G:C | D245H | 0.998 |
| 14:76171849:A:C | D245A | 0.998 |
| 14:76154374:T:A | L4Q | 0.997 |
| 14:76154754:A:G | K131E | 0.997 |
| 14:76154756:G:C | K131N | 0.997 |
dbSNP variants (sampled 300 via entrez): RS1000029146 (14:76204695 T>A), RS1000035171 (14:76182127 G>A), RS1000056319 (14:76216251 C>T), RS1000091942 (14:76166588 A>C), RS1000276509 (14:76207891 A>C,G), RS1000309202 (14:76207549 A>G), RS1000361363 (14:76172804 T>C), RS1000391296 (14:76169926 G>A), RS1000428108 (14:76197526 T>C), RS1000438533 (14:76169573 A>T), RS1000535006 (14:76188185 G>A), RS1000559102 (14:76210011 C>T), RS1000561102 (14:76183919 A>G), RS1000580302 (14:76195136 G>A), RS1000608756 (14:76231684 G>A,C)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
10 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST000094_8 | Blood pressure | 5.000000e-06 |
| GCST001320_25 | Acute lymphoblastic leukemia (childhood) | 3.000000e-06 |
| GCST001320_29 | Acute lymphoblastic leukemia (childhood) | 1.000000e-06 |
| GCST001320_4 | Acute lymphoblastic leukemia (childhood) | 4.000000e-06 |
| GCST009391_268 | Metabolite levels | 8.000000e-06 |
| GCST010083_350 | Hemoglobin levels | 7.000000e-09 |
| GCST012147_7 | Declining hemoglobin trajectory in blood donors | 3.000000e-06 |
| GCST90002383_262 | Hematocrit | 2.000000e-12 |
| GCST90002384_370 | Hemoglobin | 2.000000e-13 |
| GCST90002403_516 | Red blood cell count | 1.000000e-09 |
EFO canonical traits (6, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0006336 | diastolic blood pressure |
| EFO:0010427 | triacylglycerol 54:9 measurement |
| EFO:0004509 | hemoglobin measurement |
| EFO:0600027 | hemoglobin change measurement |
| EFO:0004348 | hematocrit |
| EFO:0004305 | erythrocyte count |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
47 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Benzo(a)pyrene | affects methylation, increases expression | 3 |
| trichostatin A | affects cotreatment, increases expression | 2 |
| sodium arsenite | increases abundance, increases expression | 2 |
| Air Pollutants | increases expression, affects cotreatment, increases abundance | 2 |
| Arsenic | increases abundance, increases expression, decreases methylation | 2 |
| Tobacco Smoke Pollution | increases expression | 2 |
| Valproic Acid | affects expression, decreases expression | 2 |
| Particulate Matter | increases abundance, increases expression, decreases expression | 2 |
| FR900359 | increases phosphorylation | 1 |
| TAK-243 | increases sumoylation | 1 |
| urushiol | increases expression | 1 |
| methylmercuric chloride | decreases expression, increases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| alpha-pinene | affects cotreatment, increases expression, increases abundance | 1 |
| nickel sulfate | decreases expression | 1 |
| methacrylaldehyde | affects cotreatment, increases expression, increases abundance | 1 |
| pentanal | decreases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | affects cotreatment, increases expression | 1 |
| abrine | increases expression | 1 |
| dorsomorphin | affects cotreatment, increases expression | 1 |
| (+)-JQ1 compound | increases expression | 1 |
| Bortezomib | increases expression | 1 |
| Irinotecan | decreases expression | 1 |
| Leflunomide | increases expression | 1 |
| Acetaminophen | increases expression | 1 |
| Acrolein | affects cotreatment, increases expression, increases abundance | 1 |
| Vehicle Emissions | decreases expression, increases abundance | 1 |
| Caffeine | affects phosphorylation | 1 |
| Coumestrol | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): acute lymphoblastic leukemia